

Board of Directors:
Ognian Donev, PhD
Vessela Stoeva
Alexander Chaushev
Bisera Lazarova
Ivan Badinski

Executive Director: **Ognian Donev, PhD**

Procurator: **Simeon Donev**

Finance Director: **Boris Borisov**

Preparer: **Lyudmila Bondzhova**

Head of Legal Department **Alexander Yotov**

Registered Address: **Sofia**
16, Iliensko Shousse Str.

Lawyer: **Ventsislav Stoev**
Stefan Vachev

Servicing Banks:
KBC Bank Bulgaria AD
DSK Bank EAD
Eurobank Bulgaria AD
ING Bank N.V. - Sofia Branch
UniCredit Bulbank AD
Citibank Europe AD, Bulgaria Branch
Municipal Bank AD

Auditors: **Baker Tilly Klitou and Partners EOOD**

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
for the year, ending 31 December 2025

	Notes	2025 BGN'000	2024 BGN'000
Revenue from contracts with customers	3	2 609 782	2 129 097
Other operating income / (losses), net	4	30 811	24 667
Changes in inventories of finished products and work in progress		21 494	19 994
Raw materials and consumables used	5	(105 339)	(103 636)
Hired services expense	6	(134 697)	(113 218)
Employee benefits expense	7	(261 772)	(206 562)
Depreciation and amortization expense	15, 16	(79 030)	(59 367)
Carrying amount of goods sold		(1 912 881)	(1 593 027)
Other operating expenses	8	(28 359)	(16 189)
Profit from operations		140 009	81 759
Impairment of non-current assets outside the scope of IFRS 9	10	(288)	(234)
Finance income	11	3 642	3 125
Finance costs	12	(24 447)	(18 546)
Finance income / (costs), net		(20 805)	(15 421)
Gain from associates and joint ventures, net	13	38 326	25 827
Gain/(Loss) on acquisition and disposal of and from subsidiaries		-	151
Profit before income tax		157 242	92 082
Income tax expense		(15 660)	(11 651)
Net profit for the year		141 582	80 431
Other comprehensive income:			
<i>Items that will not be reclassified to profit or loss:</i>			
Subsequent revaluations of property, plant and equipment	14	-	(22)
Share of other comprehensive income of associates		1 120	528
Subsequent valuations of defined benefit plans		(1 022)	(629)
Net change in the fair value of other long-term equity investments	14	(994)	(607)
Income tax relating to components of other comprehensive income that will not be reclassified	14	-	2
		(896)	(728)
<i>Items that may be reclassified to profit or loss:</i>			
Exchange differences on translating foreign operations	14	(12)	(1 089)
Share of other comprehensive income of associates	14	(2 349)	123
		(2 361)	(966)
Other comprehensive income for the period, net of tax	14	(3 257)	(1 694)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		138 325	78 737
Net profit for the year attributable to:			
Equity holders of the parent		133 522	76 310
Non-controlling interests		8 060	4 121
Total comprehensive income for the period attributable to:			
Equity holders of the parent		130 096	74 927
Non-controlling interests		8 229	3 810
Basic net earnings per share	27	BGN 0.39	0.46
Diluted net earnings per share	27	BGN -	0.46

The accompanying notes on pages 5 to 139 form an integral part of the consolidated financial statements.

Executive Director:

Ognian Donev, PhD

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
as at 31 December 2025

	Notes	2025 BGN'000	2024 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	15	413 023	392 452
Intangible assets	16	248 896	257 276
Goodwill	16	5 485	5 541
Investment property	17	7 051	7 890
Investments in associates and joint ventures	18	279 879	252 142
Other long-term equity investments	19	9 768	12 048
Long-term receivables from related parties	20	7 259	10 386
Other long-term receivables	21	4 680	8 029
Deferred tax assets		13 323	1 142
		989 364	946 906
Current assets			
Inventories	22	506 609	451 410
Trade receivables	23	455 996	305 975
Receivables from related parties	24	13 877	11 665
Other short-term receivables and assets	25	42 251	44 597
Cash and cash equivalents	26	71 603	35 730
		1 090 336	849 377
TOTAL ASSETS		2 079 700	1 796 283
EQUITY AND LIABILITIES			
Equity attributable to equity holders of the parent			
Share capital		539 158	179 100
Reserves		72 363	190 713
Other equity components (reserve on warrant issue)		-	260
Retained earnings		339 861	448 032
	27	951 382	818 105
Non-controlling interests		30 428	24 998
TOTAL EQUITY	27	981 810	843 103
LIABILITIES			
Non-current liabilities			
Long-term bank loans	28	135 144	64 652
Deferred tax liabilities		6 271	8 314
Non-current liabilities to related parties	29	16 311	19 250
Retirement benefit obligations	30	11 702	9 784
Lease liabilities	31	79 628	68 516
Government grants	32	4 662	4 358
Long-term tax liabilities		-	2 359
Other non-current liabilities	33	3 385	4 474
		257 103	181 707
Current liabilities			
Short-term bank loans	34	333 834	194 154
Current portion of long-term bank loans	28	22 825	112 499
Trade payables	35	334 805	388 085
Payables to related parties	36	35 078	3 471
Current portion of lease liabilities	31	22 038	18 671
Payables to personnel and for social security	38	30 216	26 488
Tax payables	39	15 231	9 943
Other current liabilities	40	46 760	18 162
		840 787	771 473
TOTAL LIABILITIES		1 097 890	953 180
TOTAL EQUITY AND LIABILITIES		2 079 700	1 796 283

The accompanying notes on pages 5 to 139 form an integral part of the consolidated financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova

CONSOLIDATED STATEMENT OF CASH FLOWS

for the year ending 31 December 2025

	Приложения	2025	2024
		BGN'000	BGN'000
Cash flows from operating activities			
Cash receipts from customers		2 902 130	2 468 165
Cash paid to suppliers		(2 496 074)	(2 098 249)
Cash paid to employees and for social security		(250 124)	(201 410)
Taxes paid (except income taxes)		(96 870)	(66 817)
Taxes refunded (except income taxes)		6 285	7 093
Income taxes paid		(32 626)	(13 544)
Income taxes refunded		2 608	89
Interest and bank charges paid on working capital loans		(14 400)	(13 904)
Foreign currency exchange gains/(losses), net		(4 056)	(2 360)
Other proceeds/(payments), net		1 677	(2 335)
Net cash flows from operating activities		18 550	76 728
Cash flows from investing activities			
Purchases of property, plant and equipment		(44 997)	(33 882)
Proceeds from sales of property, plant and equipment		1 267	2 865
Proceeds from sales of investment properties		352	-
Purchases of intangible assets		(97 839)	(87 509)
Proceeds from the sale of a separate part of a commercial enterprise		11 094	-
Purchases of equity investments		(4)	(9 012)
Proceeds from sale of equity investments		1 290	19
Proceeds from dividends from investments in associate and joint ventures		5 812	1 603
Proceeds from dividends from other long-term capital investments		40	39
Payments on acquisition of subsidiaries, net of cash received		(1 319)	(14 569)
Proceeds from disposal of subsidiaries, net of cash provided		-	(240)
Purchases of investments in associates and joint ventures		(699)	(685)
Proceeds from sale of investments in associates and joint ventures		4 219	1 721
Purchase of financial assets held for trading		-	(8 453)
Proceeds from sale of financial assets held for trading		1	8 584
Proceeds (Payments) from transactions with non-controlling interest, net		(5 053)	(1 237)
Loans granted to related parties		(450)	(5 172)
Loans repaid to related parties		3 000	61 727
Loans granted to third parties		(211)	(6 647)
Repaid loans granted to other enterprises		722	-
Interest received on loans and deposits		2 123	2 758
Net cash flows used in investing activities		(120 652)	(88 090)
Cash flows from financing activities			
Proceeds from short-term bank loans (including increases in overdrafts)		118 140	34 371
Repayment of short-term bank loans (including decreases in overdrafts)		(6 478)	(34 160)
Proceeds from long-term bank loans		43 016	143 409
Repayment of long-term bank loans		(33 593)	(66 607)
Proceeds from factoring		199	-
Interest and charges paid under factoring agreement		(3)	(12)
Interest and charges paid under investment purpose loans		(4 969)	(893)
Proceeds from issued shares		2 557	26 884
Lease payments		(31 074)	(22 191)
Treasury shares repurchased		(1)	(7)
Proceeds from sale of treasury shares repurchased		62 996	5 756
Dividends paid		(13 603)	(168 435)
Government grants		903	1
Proceeds/(payments) related to other equity components (warrants), net		(14)	-
Net cash flows from/(used in) financing activities		138 076	(81 884)
Net (decrease)/increase in cash and cash equivalents		35 974	(93 246)
Cash and cash equivalents at 1 January		35 629	128 875
Cash and cash equivalents at 31 December	26	71 603	35 629

The accompanying notes on pages 5 to 139 form an integral part of the consolidated financial statements.

Executive Director:**Ognian Donev, PhD****Finance Director:****Boris Borisov****Preparer:****Lyudmila Bondzhova**

SOPHARMA GROUP

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the year ending 31 December 2025

Notes	Attributable to owners of the equity of the parent								Non-controlling interests	Total equity		
	Share capital	Treasury shares	Statutory reserves	Revaluation reserve - property, plant and equipment	Reserve from financial assets at fair value through other comprehensive income	Translation of foreign operations reserve	Other equity components (reserve on warrants issue)	Retained earnings			Total	
	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000		
	Balance on 1 January 2024											
27	172 591	(57 452)	196 759	29 328	506	(1 154)	1 857	395 897	738 332	15 294	753 626	
	Changes in owners' equity for 2024											
	Capital issue	6 509	-	22 069	-	-	(1 694)	-	26 884	-	26 884	
	Effects of sold and repurchased own shares, including:	-	3 892	-	-	-	-	1 857	5 749	-	5 749	
	*repurchased shares sold	-	3 899	-	-	-	-	1 857	5 756	-	5 756	
	* acquisition of repurchased shares	-	(7)	-	-	-	-	-	(7)	-	(7)	
	Restructuring effects	-	1	-	-	-	-	-	1	(1)	-	
	Other capital components, including:	-	-	-	-	-	97	-	97	-	97	
	* transaction costs	-	-	-	-	-	97	-	97	-	97	
	Profit distribution for dividends:							(27 347)	(27 347)	-	(27 347)	
	* dividends	-	-	-	-	-	-	(14 916)	(14 916)	-	(14 916)	
	* advance six-monthly dividends from profit for 2024	-	-	-	-	-	-	(12 431)	(12 431)	-	(12 431)	
	Effects assumed by the non-controlling interest under:	-	-	-	-	-	-	(538)	(538)	5 895	5 357	
	* acquisition of/(disposal of) subsidiaries	-	-	-	-	-	-	-	-	6 826	6 826	
	* participation increase in subsidiaries	-	-	-	-	-	-	(538)	(538)	(879)	(1 417)	
	* dividend distribution	-	-	-	-	-	-	-	-	(52)	(52)	
	Total comprehensive income for the year, incl.:	-	-	-	508	(607)	(668)	-	75 694	74 927	3 810	78 737
	* net profit for the period	-	-	-	-	-	-	76 310	76 310	4 121	80 431	
	* other comprehensive income, net of taxes	-	-	-	508	(607)	(668)	-	(616)	(311)	(1 694)	
	Transfer to retained earnings	-	-	-	(2 477)	8	-	2 469	-	-	-	
	Balance at 30 September 2024											
27	179 100	(53 559)	218 828	27 359	(93)	(1 822)	260	448 032	818 105	24 998	843 103	
	Balance at 1 January 2025											
	179 100	(53 559)	218 828	27 359	(93)	(1 822)	260	448 032	818 105	24 998	843 103	
	Changes in owners' equity for 2025											
	Capital issue	360 058	-	(130 840)	-	-	(228)	(226 530)	2 460	-	2 460	
	* from exercised warrant rights	619	-	2 069	-	-	(228)	-	2 460	-	2 460	
	* from reserves	359 439	-	(132 909)	-	-	-	(226 530)	-	-	-	
	Effects of sold and repurchased own shares, including:	-	35 348	-	-	-	-	27 647	62 995	-	62 995	
	* repurchased shares sold	-	35 349	-	-	-	-	27 647	62 996	-	62 996	
	* acquired on repurchased shares	-	(1)	-	-	-	-	-	(1)	-	(1)	
	Other equity components, incl.:	-	-	18	-	-	(32)	-	(14)	-	(14)	
	* deregistered warrants	-	-	18	-	-	(18)	-	-	-	-	
	* transaction costs	-	-	-	-	-	(14)	-	(14)	-	(14)	
	Profit distribution for:	-	-	(20 776)	-	-	-	(38 746)	(38 746)	-	(38 746)	
	- dividends	-	-	-	-	-	-	(13 666)	(13 666)	-	(13 666)	
	* advance six-monthly dividends from profit for 2025	-	-	(20 776)	-	-	-	(25 080)	(45 856)	-	(45 856)	
	Effects assumed by the non-controlling interest on:	-	-	-	-	-	-	(2 738)	(2 738)	(2 799)	(5 537)	
	* acquisition of/(release from) subsidiaries	-	-	-	-	-	-	-	-	-	-	
	* distribution of dividends	-	-	-	-	-	-	-	-	(28)	(28)	
	* participation increase in subsidiaries	-	-	-	-	-	-	(260)	(260)	(4 383)	(4 643)	
	* participation decrease in subsidiaries	-	-	-	-	-	-	(2 478)	(2 478)	1 612	(866)	
	Total comprehensive income for the period, incl.:	-	-	-	1 120	(994)	(2 568)	-	132 538	130 096	8 229	138 325
	* net profit for the period	-	-	-	-	-	-	133 522	133 522	8 060	141 582	
	* other comprehensive income, net of taxes	-	-	-	1 120	(994)	(2 568)	-	(984)	(3 426)	169	(3 257)
	Transfer to retained earnings	-	-	-	(292)	634	-	(342)	-	-	-	
	Balance at 31 December 2025											
27	539 158	(18 211)	67 230	28 187	(453)	(4 390)	-	339 861	951 382	30 428	981 810	

The accompanying notes on pages 5 to 139 form an integral part of the consolidated financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova